Market Overview

UPDATE: Credit Suisse Initiates Regeneron Pharmaceutical at Outperform

Related REGN
Regeneron Downgraded At Morgan Stanley; Better Biotech Peer Plays Elsewhere
Regeneron, Sanofi Announce Approval of Praluent for Treatment of Hypercholesterolemia in EU
Sanofi Opts into Alnylam's ALN-AT3 Hemophilia Program (Zacks)

Credit Suisse initiales coverage on Regeneron Pharmaceutical (NASDAQ: REGN) with an Outperform rating and a $187 price target.

Credit Suisse said, "The primary value driver remains quarterly sales of Eylea. Proposed legislation regulating compounding pharmacies, a permanent J code in January and the launch in RVO could all help boost sales. Competitor data for Amgen's AMG145 (anti-PCSK9) and Ophthotech's Fovista have all recently been disclosed, and key clinical data for Regeneron are limited in the near term."

Regeneron Pharmaceutical closed at $144.90 on Monday.

Latest Ratings for REGN

Oct 2015Morgan StanleyDowngradesOverweightEqual-weight
Sep 2015UBSUpgradesSellBuy
Aug 2015Chardan CapitalDowngradesBuyNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (REGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters